Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Canadian Govt. Purchases 4.5M Doses of Omicron-Containing Bivalent Covid-19 Boosters from Moderna | Contract Pharma

What are you searching for?

Sign in
Breaking News

Canadian Govt. Purchases 4.5M Doses of Omicron-Containing Bivalent Covid-19 Boosters from Moderna

Doses are scheduled for delivery in 2022.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

The Government of Canada has exercised its option to purchase an additional 4.5 million doses of an Omicron-containing bivalent vaccine booster candidate from Moderna Inc., in addition to moving forward the scheduled delivery of 1.5 million doses of the bivalent vaccine candidate from 2023 to 2022.
 
Moderna and the Government of Canada have also agreed to convert six million doses of the company’s COVID-19 vaccine (Spikevax, mRNA-1273) to an Omicron-containing bivalent vaccine. The agreement is subject to regulatory approval of the Omicron-containing bivalent vaccine booster candidate by Health Canada, with doses scheduled for delivery in 2022.
 
“We thank the Government of Canada for their trust in our mRNA technology and our next-generation bivalent COVID-19 vaccine platform,” said Stéphane Bancel, Moderna’s chief executive officer. “As we have seen throughout this pandemic, the Government of Canada continues to take important steps in preparing for the winter season and protecting its people against Omicron.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics